 |
|
 |
 |
|
||||||||||||||
|
Diet Drug Rimonabant Witness Substandard Sale in Europe May 07, 2007 After badly affected by the European refutation to pay insurance reimbursement, the Diet drug rimonabant, better known as Acomplia and Zimulti, received disappointing sale of just 15 million euros in Europe in the first three months of 2007. According to the drug-maker, Sanofi-Aventis, these inadequate sales figures are just an ultimate outcome of the widespread European denial. Since its launch in last June, the pill has been utilized by over 130,000 overweight and obese people in the Europe. In some of the largest European markets, Government authorities have either refused to pay back money to patients buying Acomplia, or have restricted repayment for the costly weight loss to obese people who have uncontrolled type 2 diabetes. In a meeting with analysts, Sanofi's executive vice president, Hanspeter Spek also expressed possibility that the pill will finally hit U.S. market by the end of the year. In United States, the drug will be sold with the trade name Zimulti and safety issues repeatedly voiced by the U.S. Food and Drug Administration about the efficacy of the novel drug will be aired by an FDA advisory panel on June 13. The U.S. regulatory agency is anticipated to take a final decision
on whether to endorse rimonabant prior to the conclusion
of July. |
||||||||||||||
